Maze Therapeutics, Inc. (MAZE) Ownership
MAZE ownership summary
as of October 18, 2026- Institutions
- 107.0% of shares outstanding
- Insiders
- 1.53% of shares outstanding
- Shares outstanding
- 55.5M
- Float
- 36.8M shares available to trade
- Short interest
- 13.31% 6.6M shares short
- Days to cover
- 7.94 short interest up 15.6% vs prior month
- Institutions 106.95%
- Insiders 1.53%
MAZE top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 9.06% | 5.0M | $138.6M | +465,641 (+10.2%) | June 30, 2026 |
| 2 | TRV GP IV, LLC | 8.05% | 4.5M | $123.2M | — | June 30, 2026 |
| 3 | ARCH VENTURE CORP | 7.42% | 4.1M | $113.4M | — | June 30, 2026 |
| 4 | Deep Track Capital, LP | 6.72% | 3.7M | $102.8M | +255,007 (+7.3%) | June 30, 2026 |
| 5 | BlackRock Inc | 6.31% | 3.5M | $96.4M | +932,416 (+36.3%) | June 30, 2026 |
| 6 | Jupiter Topco LLC | 6.14% | 3.4M | $93.8M | +3.4M (0.0%) | June 30, 2026 |
| 7 | HHG PLC | 5.15% | 2.9M | $78.7M | −283,711 (−9.0%) | March 31, 2026 |
| 8 | T. Rowe Price Investment Management,Inc. | 4.69% | 2.6M | $71.7M | +2.6M (0.0%) | June 30, 2026 |
| 9 | Logos Global Management LP | 3.48% | 1.9M | $53.3M | +700,000 (+56.7%) | June 30, 2026 |
| 10 | Vanguard Capital Management, LLC | 3.20% | 1.8M | $49.0M | +342,566 (+23.9%) | June 30, 2026 |
| 11 | VR Adviser, LLC | 2.88% | 1.6M | $44.1M | — | June 30, 2026 |
| 12 | Alphabet Inc | 2.50% | 1.4M | $38.2M | — | June 30, 2026 |
| 13 | BRAIDWELL LP | 2.05% | 1.1M | $31.4M | +1.1M (0.0%) | June 30, 2026 |
| 14 | Farallon Capital Management, L.L.C. | 1.99% | 1.1M | $30.5M | +734,814 (+197.0%) | June 30, 2026 |
| 15 | FMR Inc | 1.90% | 1.1M | $29.1M | +192,745 (+22.3%) | June 30, 2026 |
| 16 | General Catalyst Group Management, LLC | 1.86% | 1.0M | $28.5M | — | June 30, 2026 |
| 17 | State Street Corp | 1.80% | 998K | $27.5M | +360,811 (+56.7%) | June 30, 2026 |
| 18 | JPMorgan Chase & Co | 1.74% | 964K | $26.5M | +905,565 (+1,549.4%) | June 30, 2026 |
| 19 | Driehaus Capital Management LLC | 1.72% | 955K | $26.3M | +318,724 (+50.1%) | June 30, 2026 |
| 20 | TRV GP V, LLC | 1.71% | 951K | $26.2M | — | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 13 holders added 12.4M shares and 1 cut 284K.
MAZE top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.54% | 1.4M | $38.9M | — | August 31, 2026 |
| 2 | iShares Russell 2000 ETF | 1.65% | 914K | $25.2M | −10,560 (−1.1%) | September 30, 2026 |
| 3 | Fidelity Select Biotechnology | 1.42% | 787K | $21.7M | +5,000 (+0.6%) | August 31, 2026 |
| 4 | Janus Henderson Hrzn Biotec E2 USD | 1.25% | 693K | $19.1M | −2,589 (−0.4%) | June 30, 2026 |
| 5 | JPMorgan Small Cap Growth A | 0.96% | 536K | $14.7M | −15,801 (−2.9%) | August 31, 2026 |
| 6 | Fidelity Small Cap Index | 0.69% | 386K | $10.6M | +2,806 (+0.7%) | July 31, 2026 |
| 7 | State Street® SPDR® S&P® PhrmctlsETF | 0.68% | 377K | $10.4M | −4,684 (−1.2%) | September 30, 2026 |
| 8 | iShares Russell 2000 Growth ETF | 0.50% | 279K | $7.7M | −353 (−0.1%) | September 30, 2026 |
| 9 | Candriam Eqs L Biotech C USD Cap | 0.50% | 278K | $7.7M | +278,167 (0.0%) | March 31, 2026 |
| 10 | iShares Biotechnology ETF | 0.48% | 267K | $7.4M | −2,024 (−0.8%) | September 30, 2026 |
| 11 | T. Rowe Price Small-Cap Stock | 0.48% | 264K | $7.3M | −176 (−0.1%) | August 31, 2026 |
| 12 | JNL/T. Rowe Price Capital Appreciation A | 0.39% | 215K | $5.9M | +215,297 (0.0%) | June 30, 2026 |
| 13 | Vanguard Russell 2000 ETF | 0.36% | 203K | $5.6M | +4,912 (+2.5%) | August 31, 2026 |
| 14 | International Biotechnology Ord | 0.36% | 200K | $5.5M | +50,917 (+34.2%) | June 30, 2026 |
| 15 | Schwab US Small-Cap ETF™ | 0.35% | 195K | $5.4M | +126 (+0.1%) | September 30, 2026 |
| 16 | BlackRock Health Sciences Opps Inv A | 0.33% | 184K | $5.1M | — | August 31, 2026 |
| 17 | T. Rowe Price Small-Cap Value | 0.31% | 173K | $4.8M | −1,582 (−0.9%) | August 31, 2026 |
| 18 | BGF World Healthscience A2 | 0.31% | 172K | $4.7M | — | June 30, 2026 |
| 19 | JPMorgan Small Cap Blend A | 0.31% | 172K | $4.7M | −3,155 (−1.8%) | August 31, 2026 |
| 20 | MEDICAL BioHealth EUR Acc | 0.29% | 159K | $4.4M | +34 (+0.0%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
MAZE insider transactions
latest 18| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | Harold Bernstein | Sell | $29.46 | 15,000 | $441,900 |
| 2026-04-01 | Amy Bachrodt | Sell | $29.44 | 2,500 | $73,600 |
| 2026-03-20 | Harold Bernstein | Sell | $49.10 | 15,000 | $736,500 |
| 2026-03-10 | Harold Bernstein | Sell | $50.45 | 30,000 | $1.5M |
| 2026-02-02 | Amy Bachrodt | Sell | $46.04 | 5,000 | $230,200 |
| 2026-02-02 | Harold Bernstein | Sell | $46.02 | 15,000 | $690,300 |
| 2026-01-29 | Atul Dandekar | Sell | $44.27 | 7,500 | $332,025 |
| 2026-01-22 | Amy Bachrodt | Sell | $45.52 | 5,000 | $227,600 |
| 2026-01-07 | Harold Bernstein | Sell | $40.20 | 25,156 | $1.0M |
| 2026-01-05 | Harold Bernstein | Sell | $40.00 | 412 | $16,480 |
| 2026-01-02 | Amy Bachrodt | Sell | $39.15 | 5,000 | $195,750 |
| 2026-01-02 | Harold Bernstein | Sell | $40.43 | 4,432 | $179,186 |
| 2025-12-30 | Amy Bachrodt | Sell | $40.08 | 5,000 | $200,400 |
| 2025-12-30 | Atul Dandekar | Sell | $40.36 | 100 | $4,036 |
| 2025-12-29 | Amy Bachrodt | Sell | $40.58 | 10,000 | $405,800 |
| 2025-12-29 | Atul Dandekar | Sell | $40.56 | 72,400 | $2.9M |
| 2025-12-29 | Harold Bernstein | Sell | $40.56 | 45,000 | $1.8M |
| 2025-09-15 | Richard H Scheller | Sell | $22.37 | 20,744 | $464,043 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
MAZE shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns MAZE
Institutional investors own 107.0% of Maze Therapeutics's shares and insiders 1.53%. The largest holder is Frazier Life Sciences Management, L.P. with 9.06% of the shares (5.0M), as of June 30, 2026. Among the top 20 institutions, 13 added shares and 1 reduced their stake in the latest filings. Short interest is 13.31% of the float, or 7.94 days of average trading volume. The share count rose 2,048.8% since 2022.
Related: MAZE analyst forecast, MAZE key metrics. See the MAZE stock overview for the latest quote and news.
MAZE ownership FAQ
Who owns the most Maze Therapeutics stock?
The largest shareholders of Maze Therapeutics are Frazier Life Sciences Management, L.P. (9.06%), TRV GP IV, LLC (8.05%), ARCH VENTURE CORP (7.42%), Deep Track Capital, LP (6.72%), BlackRock Inc (6.31%).
What percentage of Maze Therapeutics is owned by institutions?
Institutions hold 107.0% of Maze Therapeutics's shares outstanding; insiders hold 1.53%.
Which funds own Maze Therapeutics?
The largest fund holders of Maze Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (2.54%), iShares Russell 2000 ETF (1.65%), Fidelity Select Biotechnology (1.42%), Janus Henderson Hrzn Biotec E2 USD (1.25%), JPMorgan Small Cap Growth A (0.96%).
What is Maze Therapeutics's short interest?
6.6M shares of Maze Therapeutics were sold short, 13.31% of the float; at the average daily volume it would take 7.94 days to cover.
Are insiders buying or selling Maze Therapeutics?
Of the latest 18 reported insider transactions in Maze Therapeutics (since September 15, 2025), 0 were purchases and 18 were sales.
How many shares of Maze Therapeutics are outstanding?
Maze Therapeutics has 55.5M shares outstanding, of which 36.8M are in the public float.